BIA 32
Alternative Names: BIA-32Latest Information Update: 12 Jul 2022
At a glance
- Originator Lysosomal Therapeutics
- Developer BIAL
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 21 Jun 2022 BIA 32 is available for licensing as of 21 Jun 2022. https://www.bial.com/
- 21 Jun 2022 Preclinical trials in Parkinson's disease in Portugal (unspecified route) (BIAL pipeline, June 2022)